GO:0002541 activation of plasma proteins involved in acute inflammatory response: Proteolytic Cascade, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002541 describes the proteolytic activation of plasma proteins that drives the acute inflammatory response, including the complement, coagulation, and kinin systems.
• This process is initiated when plasma zymogens encounter activating surfaces or enzymes, leading to sequential cleavage and amplification.
• Key plasma proteins involved include complement components (C3, C5), coagulation factors (FII, FX, FVII), and kininogen, which are activated by proteases such as thrombin and plasmin.
• Dysregulation of this cascade contributes to immunothrombosis, sepsis, and COVID-19 severity, making it a therapeutic target.
• Experimental models using CRISPR knockout, point mutations, and knock-in of these plasma protein genes enable causal dissection of the cascade.
• EDITGENE provides CRISPR services to generate such models for studying acute inflammatory plasma protein activation.
Description
The Gene Ontology term GO:0002541, activation of plasma proteins involved in acute inflammatory response, refers to the proteolytic activation of circulating plasma proteins as part of the acute inflammatory response. This process is a cornerstone of innate immunity and hemostasis, encompassing the complement, coagulation, and kinin systems, which are triggered by injury, infection, or immune complexes. The acute inflammatory response relies on rapid amplification of these proteolytic cascades to neutralize pathogens, recruit leukocytes, and restore tissue integrity. Dysregulation of this activation underlies a spectrum of human diseases, from thrombosis and sepsis to autoimmune disorders and cancer-associated cachexia. Understanding the molecular players and regulatory mechanisms is therefore critical for developing targeted therapies. Recent multi-omics studies of COVID-19 have highlighted the central role of plasma protein activation in disease severity, underscoring the need for robust experimental models. This article synthesizes authoritative GO annotations and published literature to provide a research-grade overview of GO:0002541, its key genes, disease links, and CRISPR-based research strategies.
activation of plasma proteins involved in acute inflammatory response At A Glance
| GO ID | GO:0002541 |
|---|---|
| GO term | activation of plasma proteins involved in acute inflammatory response |
| Ontology | biological_process |
| Synonym | none |
| Major function | Proteolytic activation of plasma zymogens to drive acute inflammation, coagulation, and complement activation |
| Related processes | Complement activation, coagulation cascade, kinin system, immunothrombosis |
| Key proteases | Thrombin, plasmin, complement convertases, kallikrein |
| Cellular location | Extracellular space, plasma membrane surfaces |
| Disease relevance | Sepsis, thrombosis, COVID-19, autoimmune diseases, cancer cachexia |
What Is GO:0002541?
GO:0002541 is defined as any process that activates plasma proteins by proteolysis as part of an acute inflammatory response. In simpler terms, it is the cascade of enzymatic cleavages that converts inactive plasma zymogens into active proteases and cofactors, thereby amplifying inflammation and coagulation. This term captures the proteolytic steps that occur in the bloodstream and on cell surfaces, leading to the generation of anaphylatoxins, fibrin, and kinins.
Why Is activation of plasma proteins involved in acute inflammatory response Important in Cell Biology?
GO:0002541 is critically important because it represents the convergence point of innate immunity and hemostasis, where proteolytic cascades rapidly amplify inflammatory signals to combat infection and injury. Dysregulation of this process leads to pathological thrombosis, systemic inflammation, and organ damage, as seen in sepsis and severe COVID-19. Moreover, chronic activation contributes to cancer cachexia and autoimmune tissue damage. Understanding the precise molecular steps and regulatory checkpoints is essential for developing therapeutics that can modulate this cascade without compromising host defense.
• Central to innate immune defense against pathogens through complement and coagulation cross-talk.
• Drives immunothrombosis, a key mechanism in sepsis and COVID-19 severity.
• Contributes to acute phase response and systemic inflammation in cancer cachexia.
• Involved in crystal-induced joint inflammation such as gout.
• Modulated by acute stress via salivary markers, linking neuroendocrine and inflammatory axes.
• Provides targets for anticoagulant and anti-inflammatory therapies.
• Essential for wound healing and tissue repair through fibrin formation.
• Dysregulated in autoimmune diseases where complement activation damages host tissues.
• Serves as a biomarker source for disease severity in blood atlas studies.
• Enables research into proteolytic networks using CRISPR-edited plasma protein genes.
What Happens During activation of plasma proteins involved in acute inflammatory response?
Initiation by Activating Surfaces or Enzymes
In simple terms: The cascade starts when plasma proteins touch a trigger, like a pathogen surface or an enzyme.
The activation of plasma proteins in the acute inflammatory response is initiated when zymogens encounter activating surfaces such as microbial membranes, damaged endothelium, or immune complexes. This contact triggers conformational changes that allow autoactivation or cleavage by upstream proteases. For example, factor XII can autoactivate upon binding to negatively charged surfaces, initiating the kinin and coagulation cascades. Similarly, complement component C3 undergoes spontaneous hydrolysis or cleavage by C3 convertase, propagating the complement cascade. The initiating events are tightly regulated to prevent inappropriate activation.
Proteolytic Cleavage and Amplification
In simple terms: Once started, a series of cutting events activates more proteins, making the response bigger and bigger.
Following initiation, a series of proteolytic cleavages activate downstream zymogens, leading to exponential amplification. Thrombin, generated from prothrombin, cleaves fibrinogen to fibrin and activates factors V, VIII, and XI, as well as complement C3 and C5. Plasmin, produced from plasminogen, degrades fibrin and activates matrix metalloproteinases, linking coagulation to inflammation. Complement convertases cleave C3 and C5, releasing anaphylatoxins C3a and C5a that recruit leukocytes and enhance vascular permeability. This amplification loop ensures a rapid and robust inflammatory response.
Generation of Effector Molecules
In simple terms: The cutting produces active molecules that cause inflammation, blood clotting, and cell recruitment.
The proteolytic cascade generates effector molecules such as fibrin, bradykinin, C3a, and C5a. Fibrin forms a mesh that stabilizes clots and provides a scaffold for immune cells. Bradykinin increases vascular permeability and pain. C3a and C5a are potent chemoattractants and activators of mast cells, neutrophils, and macrophages. These effectors collectively drive the cardinal signs of inflammation: redness, heat, swelling, pain, and loss of function. Their production is balanced by inhibitors like antithrombin, C1 inhibitor, and factor H.
Cross-talk with Cellular Responses
In simple terms: The activated plasma proteins talk to immune cells, telling them to fight infection and repair damage.
Activated plasma proteins interact with cellular receptors to modulate immune responses. C5a binds to C5aR on neutrophils, triggering oxidative burst and cytokine release. Thrombin activates protease-activated receptors (PARs) on platelets and endothelial cells, promoting platelet aggregation and adhesion molecule expression. This cross-talk amplifies inflammation and recruits adaptive immune cells. Dysregulation of these interactions can lead to tissue damage, as seen in immunothrombosis during severe infections.
Resolution and Regulation
In simple terms: The body has brakes to stop the cascade once the threat is controlled.
To prevent excessive damage, the activation of plasma proteins is tightly regulated by endogenous inhibitors and decay-accelerating factors. Antithrombin inhibits thrombin and other serine proteases; C1 inhibitor controls the classical complement and contact systems; factor H and factor I regulate the alternative complement pathway. Additionally, activated proteases are cleared by protease inhibitors and receptor-mediated endocytosis. Imbalances in these regulatory mechanisms contribute to thrombotic and inflammatory diseases.
Key Genes Involved in GO:0002541 activation of plasma proteins involved in acute inflammatory response
The following genes encode key plasma proteins and proteases involved in GO:0002541, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| F2 | Encodes prothrombin, precursor of thrombin which cleaves fibrinogen and activates platelets | Central to coagulation and inflammation cross-talk |
| F10 | Encodes factor X, a serine protease that activates prothrombin | Target for anticoagulant therapy |
| F7 | Encodes factor VII, initiates extrinsic coagulation pathway | Linked to tissue factor-driven inflammation |
| F12 | Encodes factor XII, initiates contact activation and kinin system | Role in immunothrombosis |
| C3 | Central complement component, cleaved to C3a and C3b | Key mediator of acute inflammation |
| C5 | Complement component cleaved to C5a and C5b | Therapeutic target in COVID-19 |
| CFH | Encodes factor H, regulates alternative complement pathway | Mutations linked to atypical hemolytic uremic syndrome |
| SERPINC1 | Encodes antithrombin, inhibits thrombin and other proteases | Deficiency causes thrombosis |
| SERPING1 | Encodes C1 inhibitor, regulates complement and contact systems | Deficiency causes hereditary angioedema |
| PLG | Encodes plasminogen, precursor of plasmin | Links coagulation and inflammation |
| KNG1 | Encodes kininogen, precursor of bradykinin | Mediates vascular permeability |
| KLKB1 | Encodes plasma kallikrein, activates kininogen and factor XII | Role in contact activation |
| MBL2 | Encodes mannose-binding lectin, activates complement lectin pathway | Innate immune defense |
| LCN2 | Encodes lipocalin 2, an acute phase protein | Involved in stroke and inflammation |
| ORM1 | Encodes alpha-1-acid glycoprotein, acute phase reactant | Modulates drug binding and immunity |
| CRP | Encodes C-reactive protein, acute phase protein | Biomarker of inflammation |
| FGA | Encodes fibrinogen alpha chain, substrate of thrombin | Clot formation and inflammation |
How Is activation of plasma proteins involved in acute inflammatory response Regulated?
The activation of plasma proteins involved in acute inflammatory response is regulated at multiple levels. Endogenous inhibitors such as antithrombin, C1 inhibitor, and factor H provide tight control by neutralizing active proteases and preventing cascade amplification. Tissue factor pathway inhibitor (TFPI) limits the initiation of coagulation. Complement regulatory proteins like CD55 and CD59 protect host cells from complement lysis. Inflammatory mediators such as cytokines (IL-6, TNF-alpha) upregulate the synthesis of acute phase proteins in the liver, modulating the cascade. Additionally, the microbiota-derived corisin has been shown to activate coagulation during SARS-CoV-2 infection, highlighting exogenous regulation. Acute stress can also influence salivary markers of inflammation, suggesting neuroendocrine modulation.
activation of plasma proteins involved in acute inflammatory response and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| C3 | Complement-mediated inflammation in sepsis and COVID-19 | C3 knockout cell line or mouse model |
| F2 | Thrombosis and immunothrombosis | Point mutation knock-in of prothrombin variant |
| C5 | Severe COVID-19 and complementopathies | C5 overexpression in endothelial cells |
| SERPING1 | Hereditary angioedema | Knockout of SERPING1 in hepatocytes |
| LCN2 | Ischemic stroke and neuroinflammation | LCN2 knockout in neuronal cells |
Immunothrombosis and COVID-19
Dysregulated activation of plasma proteins drives immunothrombosis, a pathological condition characterized by microvascular thrombosis and inflammation. In severe COVID-19, multi-omics blood atlas studies have revealed hallmarks of disease severity linked to complement and coagulation activation. The microbiota-derived corisin further activates coagulation during SARS-CoV-2 infection, exacerbating thromboinflammation. Targeting these pathways may reduce mortality in severe viral infections.
Sepsis and Systemic Inflammation
In sepsis, excessive activation of complement and coagulation cascades leads to disseminated intravascular coagulation, organ failure, and shock. The acute inflammatory response becomes systemic, with uncontrolled generation of anaphylatoxins and thrombin. Regulatory inhibitors are overwhelmed, and cross-talk with immune cells amplifies tissue damage. Experimental models of sepsis often rely on knockout mice for complement or coagulation factors to dissect mechanisms.
Cancer Cachexia and Chronic Inflammation
Chronic activation of acute phase proteins and inflammatory mediators contributes to cancer cachexia, a wasting syndrome. Elevated levels of C-reactive protein and other acute phase reactants correlate with poor prognosis. The proteolytic activation of plasma proteins may promote muscle degradation through systemic inflammation. Targeting these pathways could ameliorate cachexia in cancer patients.
Crystal-Induced Joint Inflammation
Gout and pseudogout are driven by crystal-induced activation of complement and coagulation cascades, leading to acute joint inflammation. Monosodium urate crystals trigger the NLRP3 inflammasome and complement activation, resulting in neutrophil influx and pain. Inhibitors of plasma proteases have shown therapeutic potential in crystal-induced arthritis models.
From activation of plasma proteins involved in acute inflammatory response-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does C3 deficiency reduce immunothrombosis? | C3 knockout cell line or mouse |
| How does prothrombin mutation affect thrombin generation? | Point mutation knock-in of F2 in hepatocytes |
| Can C5a receptor blockade attenuate inflammation? | C5aR1 knockout or overexpression models |
| What is the role of factor H in complement regulation? | CFH knock-in with tagged protein |
| Does overexpression of LCN2 exacerbate stroke injury? | LCN2 overexpression in neuronal cells |
| How does corisin activate coagulation? | In vitro coagulation assays with recombinant corisin |
How to Study the activation of plasma proteins involved in acute inflammatory response Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Mass spectrometry proteomics | Cleavage products and abundance of plasma proteins | Biomarker discovery in COVID-19 |
| Chromogenic substrate assay | Enzymatic activity of thrombin or factor Xa | Validation of CRISPR knockouts |
| Complement hemolysis assay | Functional complement activity | Screening for complement regulators |
| CRISPR knockout screen | Genes affecting plasma protein activation | Discovery of novel regulators |
| Intravital microscopy | Real-time thrombus formation | Immunothrombosis studies |
| ELISA for anaphylatoxins | C3a and C5a levels | Inflammation monitoring |
| Western blot | Cleavage of zymogens | Confirming activation in cell models |
| Flow cytometry | Platelet-leukocyte aggregates | Cellular cross-talk analysis |
Proteomic Profiling of Plasma Proteins
Mass spectrometry-based proteomics can quantify the activation state of plasma proteins by detecting cleavage products or post-translational modifications. This approach has been used in COVID-19 blood atlas studies to identify severity-associated signatures. Targeted proteomics allows monitoring of specific zymogen activation in patient samples.
Functional Coagulation and Complement Assays
Chromogenic and fluorogenic substrate assays measure the activity of thrombin, factor Xa, and complement convertases. These assays are essential for validating CRISPR-edited cell models and testing inhibitors. They provide quantitative readouts of cascade activation.
CRISPR Screening for Regulators
Genome-wide CRISPR knockout screens can identify genes that regulate plasma protein activation in cell-based models. Libraries targeting proteases, inhibitors, and signaling pathways enable unbiased discovery. Hits can be validated with individual knockouts.
Imaging of Thrombus Formation
Intravital microscopy and microfluidic models visualize platelet aggregation and fibrin formation in real time. These methods link molecular activation to cellular outcomes. They are useful for studying immunothrombosis.
How CRISPR Can Be Used to Study GO:0002541 activation of plasma proteins involved in acute inflammatory response
Knockout
CRISPR knockout of genes encoding plasma proteins or their regulators (e.g., C3, F2, SERPINC1) can abolish specific cascade branches, allowing researchers to dissect their contribution to acute inflammation. Knockout cell lines, such as hepatocytes or endothelial cells, provide clean backgrounds for functional assays. These models are invaluable for target validation in immunothrombosis.
Point Mutation
Point mutations can mimic naturally occurring variants that alter protein function, such as prothrombin G20210A or factor V Leiden. CRISPR point mutation knock-in in cell lines enables study of these variants in a controlled setting. This approach helps link genotype to phenotype in coagulation and inflammation.
Knock-in
Knock-in of tagged or reporter genes (e.g., GFP-tagged C3) allows real-time tracking of protein activation and localization. Tagged knock-in models facilitate imaging and proteomic pull-down studies. They are useful for understanding spatiotemporal dynamics of plasma protein activation.
Overexpression
Overexpression of key plasma proteins or proteases (e.g., C5a, thrombin) can amplify the inflammatory response in cell models. This is achieved by CRISPR activation or lentiviral delivery. Overexpression models help identify gain-of-function effects and test inhibitors.
How EDITGENE Supports activation of plasma proteins involved in acute inflammatory response Research
Researchers studying activation of plasma proteins involved in acute inflammatory response-related genes often need to determine whether a candidate gene is causally involved in the cascade or merely a bystander. CRISPR-based genome editing provides the gold standard for establishing causality by creating isogenic models with precise genetic alterations. EDITGENE offers a comprehensive suite of services to generate such models, enabling rigorous mechanistic studies.
Contact EDITGENE today to design your custom CRISPR model for activation of plasma proteins involved in acute inflammatory response research.
Frequently Asked Questions About activation of plasma proteins involved in acute inflammatory response
What is GO:0002541?
GO:0002541 is a Gene Ontology term for the activation of plasma proteins involved in acute inflammatory response, defined as any process activating plasma proteins by proteolysis as part of an acute inflammatory response.
What genes are involved in activation of plasma proteins involved in acute inflammatory response?
Key genes include complement components (C3, C5), coagulation factors (F2, F10, F7, F12), and regulators (SERPINC1, SERPING1, CFH), among others.
How does the acute inflammatory response activate plasma proteins?
It activates plasma proteins through proteolytic cascades triggered by injury or infection, leading to amplification and generation of effector molecules like C3a, C5a, and fibrin.
What diseases are associated with dysregulated plasma protein activation?
Diseases include immunothrombosis, sepsis, COVID-19, cancer cachexia, and crystal-induced joint inflammation.
What is the role of complement in acute inflammation?
Complement proteins like C3 and C5 are cleaved to produce anaphylatoxins that recruit immune cells and enhance vascular permeability.
How can CRISPR be used to study plasma protein activation?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal dissection of individual genes in the cascade.
What are the main proteases in this process?
Thrombin, plasmin, and complement convertases are central proteases that cleave zymogens to active forms.
How is the activation of plasma proteins regulated?
It is regulated by inhibitors such as antithrombin, C1 inhibitor, and factor H, as well as by cytokine-mediated acute phase responses.
What experimental models are used to study GO:0002541?
Models include knockout cell lines, point mutation knock-ins, and overexpression systems, often combined with functional coagulation and complement assays.
Why is immunothrombosis relevant to COVID-19?
Immunothrombosis, driven by plasma protein activation, contributes to microvascular thrombosis and severity in COVID-19, as shown by blood atlas studies.
Conclusion
GO:0002541 encompasses the proteolytic activation of plasma proteins that is fundamental to acute inflammation and hemostasis. Its dysregulation is implicated in a wide range of diseases, from thrombosis to cancer cachexia. Understanding the molecular players and regulatory mechanisms is essential for therapeutic development. CRISPR-based models offer powerful tools to dissect these pathways, and EDITGENE provides the expertise to generate such models efficiently.
References
- 1. Kaiser R et al.. 2025. Recent Advances in Immunothrombosis and Thromboinflammation.. Thromb Haemost 125(12):1181-1194 PMID: 40311639
- 2. COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. Electronic address: julian.knight@well.ox.ac.uk et al.. 2022. A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.. Cell 185(5):916-938.e58 PMID: 35216673
- 3. Zhao RY et al.. 2023. Role of lipocalin 2 in stroke.. Neurobiol Dis 179:106044 PMID: 36804285
- 4. Fournier T et al.. 2000. Alpha-1-acid glycoprotein.. Biochim Biophys Acta 1482(1-2):157-71 PMID: 11058758
- 5. Tsuruga T et al.. 2024. Role of microbiota-derived corisin in coagulation activation during SARS-CoV-2 infection.. J Thromb Haemost 22(7):1919-1935 PMID: 38453025
- 6. Robinson TP et al.. 2023. The impact of inflammation and acute phase activation in cancer cachexia.. Front Immunol 14:1207746 PMID: 38022578
- 7. Oliviero F et al.. 2003. [Crystal-induced joint inflammation].. Reumatismo 55(1):16-27 PMID: 12649696
- 8. Slavish DC et al.. 2015. Salivary markers of inflammation in response to acute stress.. Brain Behav Immun 44:253-69 PMID: 25205395
